2024
BIO101 as a candidate oral treatment for DMD patients is supported by the results of two randomized clinical trials in
vulnerable populations, Cendrine Tourette, Waly Dioh, Sandrine Rabut, Serge Camelo, Jean Mariani, Rob Van Maanen, Stanislas Veillet